Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer

An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers